Compare Campbell Soup Co. (CPB) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Nuwellis Inc — how do they compare? Campbell Soup Co. trades at $21.82 (market cap $6.59B), while Nuwellis Inc trades at $3.25 (market cap $1.17M). The key difference: Campbell Soup Co. is far larger — about 5632.5× Nuwellis Inc's market cap, and Campbell Soup Co. pays a 7.06% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| CPB | NUWE | |
|---|---|---|
Market Cap | $6.59B | $1.17M |
Sector | Consumer Staples | Technology |
52-Week High | $34.03 | $558.26 |
52-Week Low | $20.00 | $2.80 |
Enterprise Value | $13.20B | -$636.97K |
Dividend Yield | 7.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.15, up 0.36% with neutral technical signals. The stock shows modest valuation metrics with P/E of 10.85 and P/S of 0.67, while recent earnings show mixed results with Q1 2026 beating expectations. Revenue growth remains stable at $10.25B for 2025, though profit margins have compressed from historical levels. The company maintains strong cash flow generation and recently launched new product innovations including protein soups and gluten-free options.
CPB offers value investors an attractive 7% dividend yield and reasonable valuation, but faces margin pressure and competitive headwinds. Analyst consensus leans cautious with 58.6% hold ratings, though recent product launches and cost initiatives provide potential catalysts. Key risks include ongoing margin compression and consumer spending sensitivity in the current economic environment.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025 despite $8.27M revenue, reflecting negative profit margins and cash flow challenges. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026, alongside a CEO transition to Mike McCormick effective June 30, 2026.
Outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is split evenly between Buy and Hold. Key risks include execution in revenue growth and reliance on financing. Upside depends on successful commercialization of Aquadex therapy and FDA label expansion for pediatric patients.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
